Approval for an upgrade of the device including a modification of the main console, computer and software.  The device, as modified, will be marketed under the trade name tmx-3000 thermatrx office thermotherapy system and is indicated for the treatment of symptomatic benign prostatic hyperplasia (bph) in men who have a minimum prostatic urethra length f 25 mm and a total prostate volume between 30 and 100 cc.